文献速递类风湿关节炎

高类风湿因子水平对类风湿关节炎患者对certolizumab pegol应答的影响:REALISTIC IIIb期试验的事后分析

Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial.
PubMed 文献 · RMD Open · 2026-01-30

该事后分析基于REALISTIC IIIb期试验,评估类风湿因子(RF)水平和既往TNF抑制剂应答不足/不耐受对certolizumab pegol(CZP)疗效的影响。930例RA患者随机接受CZP或安慰剂12周,随后开放标签CZP至36周。结果显示,无论RF水平高低及既往TNFi使用情况,CZP治疗的临床应答相似,支持CZP对高RF水平及既往TNFi应答不足患者有效。

要点

  • 高RF水平(≥180 kU/L)与低RF水平(<180 kU/L)患者对CZP的临床应答相似。
  • 既往TNFi应答不足/不耐受不影响CZP的疗效。
  • CZP治疗应答从第12周至第36周普遍改善,各亚组间疗效相似。

核心结论

  • 高和低RF水平患者对CZP治疗的临床应答相似,无论既往是否对TNFi应答不足或不耐受。
  • 这些发现扩展了既往观察,支持CZP作为高RF水平及既往TNFi应答不足RA患者的有效治疗。

研究设计与样本

  • REALISTIC IIIb期试验的事后分析,患者随机接受CZP(第0、2、4周400 mg,之后每2周200 mg)或安慰剂12周,随后开放标签CZP至少16周。
  • 共纳入930例患者:751例随机至CZP,179例随机至安慰剂。
  • 数据按基线RF水平(≤第三四分位数(≤Q3;<180 kU/L) vs 第四四分位数(Q4;「高RF」;≥180 kU/L))和既往TNFi使用(未使用TNFi vs TNFi应答不足/不耐受)分层。

主要发现

  • 第12周时,CZP随机患者疾病活动度显著改善且相似, regardless of RF水平和既往TNFi使用,而安慰剂随机患者未改善。
  • CZP治疗患者(包括安慰剂随机后切换者)的应答 generally 改善至第36周,各亚组间疗效相似。

关键数值与推荐

  • 报告至第36周的结局包括DAS28-CRP和CDAI评分、DAS28-CRP <2.6率和CDAI缓解率(CDAI ≤2.8)及各组分。
  • RF分层阈值:≤Q3为<180 kU/L,Q4(高RF)为≥180 kU/L。

临床怎么用

  • 对于高RF水平或既往TNFi应答不足/不耐受的RA患者,CZP仍可作为有效治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of rheumatoid factor (RF) levels and previous inadequate responses/intolerance to tumour necrosis factor inhibitors (TNFi-IR) on the efficacy of certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) through a post hoc analysis of the RA Evaluation in Subjects Receiving TNF Inhibitor CZP (REALISTIC) trial. METHODS: In the phase IIIb REALISTIC trial, patients with RA were randomised to CZP (400 mg at weeks 0, 2 and 4, then 200 mg every 2 weeks) or placebo (PBO) for 12 weeks, followed by open-label CZP (minimum 16 weeks). Outcomes reported to week 36 include Disease Activity Score 28 C-reactive protein (DAS28-CRP) and Clinical Disease Activity Index (CDAI) scores, rates of DAS28-CRP <2.6 and CDAI remission (CDAI ≤2.8) and components of each. Data were stratified by baseline RF level (≤3rd quarter (≤Q3; <180 kU/L) vs 4th quarter (Q4; 'high RF'; ≥180 kU/L)) and prior TNFi use (TNFinaïve vs TNFi-IR). RESULTS: A total of 930 patients were included: 751 CZP-randomised and 179 PBO-randomised. At week 12, CZP-randomised patients experienced marked and similar improvements in disease activity, irrespective of RF level and prior TNFi use, while PBO-randomised patients did not. Responses generally improved through week 36 in CZP-treated patients (including PBO-randomised switchers), with similar efficacy across subgroups. CONCLUSIONS: Patients with high and low RF levels experienced similar clinical responses to CZP treatment, irrespective of previous inadequate responses or intolerance to TNFis. These findings expand previous observations, supporting CZP as an effective treatment for patients with RA who have high RF levels and prior inadequate responses to TNFis. TRIAL REGISTRATION NUMBER: NCT00717236.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Smolen JS, Mikuls TR, Galloway J, et al. Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial. RMD Open. 2026. PMID: 41617358. doi:10.1136/rmdopen-2025-006094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。